Bastiano Sanna, Ph.D., joined Vertex in 2019 and is the company’s Executive Vice President, Chief of Cell and Genetic Therapies. In this role, Dr. Sanna is responsible for advancing research, development and manufacturing for all of Vertex’s cell and genetic therapy programs, including hemoglobinopathies, Duchenne muscular dystrophy, myotonic dystrophy type 1 and type 1 diabetes. He will also oversee the future Vertex Cell and Genetic Therapies research site, which is expected to open in 2021 at Innovation Square in Boston’s Seaport District.
Dr. Sanna was previously the CEO of Semma Therapeutics, which was acquired by Vertex in 2019. Under his leadership, Semma’s pioneering work to develop cell therapy treatments for those living with type 1 diabetes significantly advanced.
Prior to Semma, Dr. Sanna was Chief Operating Officer at Magenta Therapeutics, where he was responsible for operations, finance, clinical development and program management. Prior to Magenta, Dr. Sanna served on the leadership team of Novartis’ Cell and Gene Therapy Unit as the Global Program Head of Stem Cell Transplant and early programs, where he oversaw clinical, regulatory, CMC and commercial aspects of programs in bone marrow transplant and CAR-T cell therapies. He also served as Global Head of Strategic Planning and Portfolio Management at the Novartis Institutes for BioMedical Research, where he was responsible for global portfolio management of all Novartis’ research programs, from discovery through Phase II across all disease areas.
Dr. Sanna received a Ph.D. in Biotechnology from the University of Sassari.
What is Bastiano Sanna's net worth?
The estimated net worth of Bastiano Sanna is at least $13.98 million as of May 5th, 2023. Dr. Sanna owns 34,888 shares of Vertex Pharmaceuticals stock worth more than $13,981,715 as of April 25th. This net worth estimate does not reflect any other assets that Dr. Sanna may own. Learn More about Bastiano Sanna's net worth.
How do I contact Bastiano Sanna?
Has Bastiano Sanna been buying or selling shares of Vertex Pharmaceuticals?
Bastiano Sanna has not been actively trading shares of Vertex Pharmaceuticals over the course of the past ninety days. Most recently, Bastiano Sanna sold 2,850 shares of the business's stock in a transaction on Monday, May 8th. The shares were sold at an average price of $350.00, for a transaction totalling $997,500.00. Following the completion of the sale, the executive vice president now directly owns 32,038 shares of the company's stock, valued at $11,213,300. Learn More on Bastiano Sanna's trading history.
Who are Vertex Pharmaceuticals' active insiders?
Vertex Pharmaceuticals' insider roster includes David Altshuler (EVP), Kristen Ambrose (CAO), Stuart Arbuckle (COO), Sangeeta Bhatia (Director), Jonathan Biller (EVP), Joshua Boger (Director), Carmen Bozic (CMO), Reshma FASN (M.D.), Reshma Kewalramani (CEO), Yuchun Lee (Director), Jeffrey Leiden (Chairman), Joy Liu (SVP), Margaret McGlynn (Director), Michael Parini (EVP), Amit Sachdev (EVP), Bruce Sachs (Director), Bastiano Sanna (EVP), Paul Silva (CAO), Ian Smith (COO), Ourania Tatsis (EVP), and Charles Wagner, Jr. (CFO). Learn More on Vertex Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Vertex Pharmaceuticals?
During the last year, insiders at the pharmaceutical company sold shares 32 times. They sold a total of 115,042 shares worth more than $42,520,712.26. The most recent insider tranaction occured on February, 26th when EVP Ourania Tatsis sold 354 shares worth more than $150,697.80. Insiders at Vertex Pharmaceuticals own 0.2% of the company.
Learn More about insider trades at Vertex Pharmaceuticals. Information on this page was last updated on 2/26/2024.
